CABENUVA KIT Drug Patent Profile

Which patents cover Cabenuva Kit, and what generic alternatives are available?

Cabenuva Kit is a drug marketed by Viiv Hlthcare and is included in one NDA. There are eight patents protecting this drug.

This drug has two hundred and eighty-eight patent family members in forty-six countries.

The generic ingredient in CABENUVA KIT is cabotegravir; rilpivirine. One supplier is listed for this compound. Additional details are available on the cabotegravir; rilpivirine profile page.

DrugPatentWatch^® Generic Entry Outlook for Cabenuva Kit

Cabenuva Kit was eligible for patent challenges on January 21, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2031. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for CABENUVA KIT

International Patents:	288
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CABENUVA KIT

US Patents and Regulatory Information for CABENUVA KIT

CABENUVA KIT is protected by eight US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes			Y
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes			Y

International Patents for CABENUVA KIT

When does loss-of-exclusivity occur for CABENUVA KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

Montenegro

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CABENUVA KIT around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	200803423	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Hungary	S1500051
Cyprus	1120564
European Patent Office	3284520	DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)

Supplementary Protection Certificates for CABENUVA KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3808743	C 2022 032	Romania		PRODUCT NAME: COMBINATIE DE RILPIVIRINA SAU UN N-OXID, O SARE DE ADITIE ACCEPTABILA FARMACEUTIC, INCLUSIV SAREA CLORHIDRAT A RILPIVIRINEI SAU O FORMA IZOMERICA STEREOCHIMICA A RILPIVIRINEI SI EMTRICITABINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/737/001-002; DATE OF NATIONAL AUTHORISATION: 20111128; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/737/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20111128
1632232	300852	Netherlands		PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINEHYDROCHLORIDE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623
3808743	2022C/531	Belgium		PRODUCT NAME: EEN COMBINATIE VAN RILPIVIRINE OF EEN FARMACEUTISCH AANVAARDBAAR ADDITIEZOUT VAN RILPIVIRINE, EN EMTRICITABINE; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001-002 20111128
1419152	CR 2012 00019	Denmark		PRODUCT NAME: RILPIVIRIN OG FARMACEUTISK ACCEPTABLE ADDITIONSSALTE DERAF, HERUNDER HYDROGENCHLORIDSALTET AF RILPIVIRIN; REG. NO/DATE: EU/1/11/736/001 20111128

CABENUVA KIT: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

This report details the investment fundamentals and patent landscape for Cabenuva Kit, a long-acting injectable antiretroviral therapy for HIV. The analysis focuses on market positioning, competitive landscape, patent protection, and projected financial performance to inform R&D and investment decisions.

What is Cabenuva Kit?

Cabenuva Kit is a combination of cabotegravir and rilpivirine, co-developed by ViiV Healthcare (majority-owned by GSK) and Janssen Pharmaceuticals. It is the first and only long-acting injectable treatment for the maintenance of virologically suppressed HIV-1 infection in adults and adolescents (aged 12 years and older and weighing at least 35 kg). The therapy is administered intramuscularly every four weeks or every eight weeks after an initial oral lead-in period. The U.S. Food and Drug Administration (FDA) approved Cabenuva for every-four-week dosing on January 21, 2021, and for every-eight-week dosing on May 20, 2021. European Medicines Agency (EMA) approval for both dosing frequencies followed in 2021. [1, 2]

Market Opportunity and Competitive Landscape

The global HIV treatment market is substantial and continues to grow, driven by increasing diagnosis rates, improved treatment adherence, and the shift towards more convenient dosing regimens. Cabenuva Kit targets a segment of the HIV market that prioritizes long-acting injectables over daily oral pills, addressing issues of pill fatigue, stigma, and adherence challenges.

Key Market Drivers:

• Adherence and Convenience: Long-acting injectables offer a significant advantage for patients who struggle with daily pill regimens due to forgetfulness, lifestyle factors, or a desire for greater discretion.
• Reduced Pill Burden: Eliminating the need for daily oral medication can improve patient quality of life.
• Underserved Patient Populations: Cabenuva Kit is particularly relevant for individuals who experience challenges with daily oral therapy adherence.
• Growing Global HIV Market: The market for antiretroviral therapies is projected to expand due to increased access to testing and treatment, particularly in low- and middle-income countries.

Competitive Landscape:

The competitive landscape for HIV treatment is characterized by established oral therapies and emerging long-acting injectables.

• Oral Daily Regimens: The majority of the HIV market is currently served by daily oral antiretroviral therapies. Major competitors include Gilead Sciences (Biktarvy, Descovy), ViiV Healthcare (Triumeq, Tivicay), and Merck (Isentress). These therapies represent the established standard of care.
• Other Long-Acting Injectables: While Cabenuva Kit is the first long-acting injectable for maintenance therapy, other long-acting options are in development or have been approved for different indications. For instance, Lenacapavir (Sunlenca) from Gilead Sciences is a long-acting capsid inhibitor approved for heavily treatment-experienced individuals with multi-drug resistant HIV-1 infection, administered subcutaneously every six months. [3] Future competition may arise from other companies developing novel long-acting formulations.
• Switching Dynamics: The primary competitive strategy for Cabenuva Kit involves encouraging patients on stable oral regimens to switch to the injectable format. This requires extensive patient and prescriber education, robust clinical trial data demonstrating non-inferiority, and favorable formulary access.

Cabenuva Kit's unique positioning as a first-in-class long-acting injectable maintenance therapy provides a significant first-mover advantage. However, continued innovation in oral therapies and the emergence of other long-acting options necessitate ongoing market vigilance.

Patent Landscape and Exclusivity

The patent portfolio surrounding Cabenuva Kit is critical to its long-term commercial viability. ViiV Healthcare and Janssen have secured patent protection for the active pharmaceutical ingredients (APIs), formulations, manufacturing processes, and methods of use.

Key Patents and Exclusivity Periods:

The core patents for cabotegravir and rilpivirine, the APIs in Cabenuva Kit, are expected to provide market exclusivity for a considerable period.

• Cabotegravir Patents: Patents covering cabotegravir's chemical structure and uses are foundational. Key patents are expected to expire in the mid-to-late 2030s, though this can vary by jurisdiction and patent term extensions. For example, U.S. Patent No. 8,901,120, related to cabotegravir, is listed with an expiration date of March 14, 2031. [4]
• Rilpivirine Patents: Rilpivirine, also known as Edurant, has its own patent portfolio. U.S. Patent No. 7,276,492, covering rilpivirine, is listed with an expiration date of November 10, 2025. [5] However, it is crucial to note that formulations and methods of use patents can extend exclusivity beyond the API patent expiration.
• Formulation and Combination Patents: Patents covering the specific long-acting injectable formulations of cabotegravir and rilpivirine, as well as their combination in Cabenuva Kit, are crucial. These patents may extend exclusivity. For instance, patents related to injectable compositions and methods of administering long-acting antiretrovirals are expected to provide protection well into the 2030s.
• Regulatory Exclusivity: In addition to patent protection, Cabenuva Kit benefits from regulatory exclusivity periods granted by regulatory authorities. In the U.S., this typically includes 5 years for a New Chemical Entity (NCE) and potentially longer periods if the drug is approved for a new indication or as a pediatric formulation. For Cabenuva, the 5-year NCE exclusivity is a baseline, with potential extensions applicable. [6] In Europe, a 10-year data exclusivity period applies, which can be extended to 11 years if a new therapeutic indication is approved during the first 8 years. [7]

Potential Threats to Exclusivity:

• Patent Challenges: Competitors may challenge the validity or inventiveness of existing patents, potentially leading to earlier market entry for generics.
• Abbreviated New Drug Application (ANDA) Filings: Generic manufacturers can file ANDAs seeking approval to market generic versions of Cabenuva Kit upon patent expiry or successful patent challenges.
• Biosimilar Development: While Cabenuva Kit is a small molecule drug and not a biologic, the concept of "biosimilar" competition is relevant for long-acting injectable formulations. The complexity of such formulations might present barriers to rapid generic entry.

The patent strategy for Cabenuva Kit appears robust, aiming to secure market exclusivity through a combination of API, formulation, and method-of-use patents, augmented by regulatory exclusivities.

Financial Performance and Projections

Cabenuva Kit's financial performance is driven by its adoption rate among healthcare providers and patients, pricing, and market access. ViiV Healthcare has reported strong initial uptake.

Sales Performance:

• 2021: Cabenuva Kit generated approximately £279 million ($386 million) in sales in its first full year of launch, exceeding initial expectations. [8]
• 2022: Sales increased to £565 million ($746 million), demonstrating continued growth. [9]
• 2023 (Year-to-Date as of Q3): ViiV Healthcare reported £752 million ($937 million) in Cabenuva sales for the first nine months of 2023. [10] This trajectory indicates significant year-over-year growth and strong market penetration.
• Projected Sales: Analysts project continued sales growth for Cabenuva Kit, with consensus estimates suggesting peak annual sales could exceed $2 billion. This projection is contingent on continued market adoption, expansion into new geographies, and effective management of the competitive landscape.

Factors Influencing Financial Projections:

• Dosing Frequency: The approval of the every-eight-week dosing regimen has been a significant driver of sales, enhancing patient convenience and potentially broadening the market.
• Geographic Expansion: Successful launches and market access in key international markets will be critical for sustained growth.
• Pricing and Reimbursement: Pricing strategies and favorable reimbursement policies from payers are essential for commercial success, particularly in diverse healthcare systems.
• Competition: The entry of new long-acting therapies or significant advancements in oral treatments could impact market share.
• Adherence and Persistence Data: Real-world evidence supporting high adherence and persistence rates with Cabenuva Kit will bolster its value proposition and support market access.

The financial outlook for Cabenuva Kit is positive, supported by strong initial sales, a growing market for convenient HIV treatments, and a projected expansion of its addressable patient population.

Regulatory Status and Pipeline

Cabenuva Kit has received approvals in major markets and continues to be the subject of regulatory review for potential label expansions or new indications.

Global Approvals:

• United States: FDA approval for every-four-week (January 2021) and every-eight-week (May 2021) dosing.
• Europe: EMA approval for both dosing frequencies (2021).
• Other Markets: Approvals have been secured in numerous other countries, including Canada, Australia, and various nations across Asia and Latin America.

Pipeline Developments:

While Cabenuva Kit is a mature product, ViiV Healthcare and its partners continuously evaluate opportunities for label expansion or further optimization. Potential areas for pipeline development related to long-acting injectables include:

• Prevention (PrEP): Cabotegravir is also being investigated for HIV prevention as a long-acting injectable (e.g., Apretude, approved for PrEP in December 2021). [11] The long-acting injectable platform is central to ViiV's strategy for both treatment and prevention.
• New Formulations: Research into novel delivery systems or improved pharmacokinetic profiles for existing or new long-acting antiretrovirals.
• Combination Therapies: Development of new long-acting combination products that could offer broader spectrum activity or address emerging resistance patterns.

The regulatory pathway for Cabenuva Kit has been largely successful, with broad market access established. Ongoing pipeline activities will be key to maintaining a competitive edge and addressing future needs in HIV management.

Investment Rationale

Cabenuva Kit presents a compelling investment opportunity within the pharmaceutical sector, specifically in the growing HIV therapeutic area. Its first-in-class status, robust patent protection, and strong market uptake underpin its financial potential.

Key Investment Considerations:

• First-Mover Advantage: Cabenuva Kit established the long-acting injectable market for HIV maintenance therapy, creating a significant barrier to entry for competitors.
• Addressable Market: The shift towards convenience and adherence solutions in HIV treatment is a secular trend, expanding the potential patient pool for long-acting options.
• Patent Strength: The projected expiry dates of key patents provide a substantial period of market exclusivity, allowing for sustained revenue generation.
• Strong Sales Momentum: The product has exceeded initial sales expectations, indicating strong physician and patient acceptance.
• Pipeline Synergies: ViiV Healthcare's focus on long-acting injectables extends to HIV prevention, creating a synergistic portfolio of innovative solutions.

Risks and Mitigation:

• Competitive Response: The success of Cabenuva Kit will likely spur increased competition, including from other long-acting injectables and potentially improved oral therapies. Mitigation involves continuous innovation, strong pharmacovigilance, and ongoing market education.
• Payer Access and Pricing Pressures: Securing favorable reimbursement and managing pricing in a cost-conscious healthcare environment are critical. Mitigation involves demonstrating significant value to payers through improved adherence and reduced long-term healthcare costs.
• Manufacturing and Supply Chain: Ensuring consistent and reliable supply of complex injectable formulations is paramount. Mitigation requires robust supply chain management and manufacturing capacity.

Cabenuva Kit is positioned as a significant contributor to ViiV Healthcare's revenue growth and a testament to innovation in HIV management. Its established market position, coupled with a favorable patent and regulatory environment, supports its continued commercial success.

Key Takeaways

• Cabenuva Kit is the first and only long-acting injectable for HIV maintenance therapy, offering a significant advantage in adherence and convenience.
• The product has demonstrated strong sales growth since its launch, exceeding initial projections and indicating robust market adoption.
• A comprehensive patent portfolio for cabotegravir and rilpivirine, along with formulation patents, is expected to provide market exclusivity through the mid-to-late 2030s.
• The market for long-acting HIV treatments is expanding, driven by patient preferences and the need for improved adherence solutions.
• Cabenuva Kit represents a strategic asset for ViiV Healthcare, with projected peak sales potentially exceeding $2 billion annually.

Frequently Asked Questions

1. What is the primary advantage of Cabenuva Kit over daily oral HIV medications? Cabenuva Kit's primary advantage is its long-acting injectable formulation, administered every four or eight weeks, which eliminates the need for daily pill-taking. This addresses challenges associated with pill fatigue, stigma, and adherence for certain patient populations.

2. What are the key components of Cabenuva Kit? Cabenuva Kit is a combination of two active pharmaceutical ingredients: cabotegravir, an integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI).

3. How does the patent protection for Cabenuva Kit compare to other HIV treatments? Cabenuva Kit benefits from a layered patent strategy encompassing the individual APIs (cabotegravir and rilpivirine), their specific long-acting injectable formulations, and methods of use. Key API patents are expected to expire in the mid-to-late 2030s, with formulation and method-of-use patents potentially extending exclusivity further, offering a comparable or longer protection period than many established oral therapies.

4. What is the projected market size for long-acting injectable HIV therapies? While precise market size figures for the long-acting injectable segment are evolving, industry analysts project this niche to grow significantly, with consensus estimates suggesting peak annual sales for Cabenuva Kit alone could surpass $2 billion, indicating substantial market potential for this class of therapy.

5. Are there any significant risks to the long-term commercial viability of Cabenuva Kit? Key risks include the emergence of competitive long-acting injectable therapies, potential patent challenges from generic manufacturers, and ongoing payer pressure on pricing and reimbursement. Continuous innovation and demonstrating superior patient outcomes are critical for mitigating these risks.

Citations

[1] ViiV Healthcare. (2021, January 21). FDA approves Cabenuva (cabotegravir; rilpivirine), the first and only long-acting injectable treatment for HIV-1 virologically suppressed adults. [Press release]. [2] ViiV Healthcare. (2021, July 28). EMA approves Cabenuva (cabotegravir; rilpivirine) for the treatment of HIV-1 infection. [Press release]. [3] Gilead Sciences. (2023, December 22). FDA Approves Gilead’s Sunlenca™ (lenacapavir) for heavily treatment-experienced people with multi-drug resistant HIV-1 infection. [Press release]. [4] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website - specific search required for patent details]. [5] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website - specific search required for patent details]. [6] U.S. Food and Drug Administration. (2020). Guidance for Industry: New Drug Applications. [7] European Medicines Agency. (2019). Guideline on the development and submission of dossiers for applications for regulatory data protection. [8] ViiV Healthcare. (2022, February 23). ViiV Healthcare announces 2021 full year results. [Press release]. [9] ViiV Healthcare. (2023, February 22). ViiV Healthcare announces 2022 full year results. [Press release]. [10] ViiV Healthcare. (2023, October 26). ViiV Healthcare announces third quarter 2023 results. [Press release]. [11] ViiV Healthcare. (2021, December 20). FDA approves Apretude (cabotegravir extended-release injectable suspension) for HIV-1 pre-exposure prophylaxis. [Press release].